Zobrazeno 1 - 10
of 11
pro vyhledávání: '"Ryo, Ito"'
Autor:
Ryo Ito, Yoshitomi Yayoi, Koji Watanabe, Teruki Hamada, Yasuhiro Hirata, Yasufumi Miyamoto, Seiji Miwatashi, Nobuyuki Takakura, Kazuaki Takami, Yoshihiko Hirozane, Naoyoshi Noguchi, Yusuke Moritoh, Mitsugi Ookawara, Hideki Furukawa, Jumpei Aida, Masanori Watanabe, Hitomi Yuko, Tsuyoshi Maekawa
Publikováno v:
Journal of Medicinal Chemistry. 63:10352-10379
GPR40/FFAR1 is a G-protein-coupled receptor expressed in pancreatic β-cells and enteroendocrine cells. GPR40 activation stimulates secretions of insulin and incretin, both of which are the pivotal regulators of glycemic control. Therefore, a GPR40 a
Autor:
Mitsugi Ookawara, Koji Takeuchi, Yusuke Moritoh, Hitomi Ogino, Tomoki Yoshihara, Masanori Watanabe, Shin-ichi Abe, Yoshimasa Ishimura, Ryo Ito, Yoshiyuki Tsujihata, Hirohisa Miyashita, Yasufumi Miyamoto, Nobuhiro Nishigaki, Hikaru Ueno, Yukio Yamada
Publikováno v:
Diabetes. 68
GPR40/FFAR1 is a G-protein-coupled receptor expressed in pancreatic islets and enteroendocrine cells. SCO-267 is a novel full agonist of GPR40 being developed as a treatment for type 2 diabetes and obesity. The efficacy of SCO-267 was investigated in
Autor:
Nobuhiro Nishigaki, Hikaru Ueno, Yasufumi Miyamoto, Hirohisa Miyashita, Koji Takeuchi, Yoshiyuki Tsujihata, Minoru Maruyama, Ryo Ito, Hitomi Ogino, Yusuke Moritoh, Shin-ichi Abe
Publikováno v:
PLoS ONE, Vol 14, Iss 9, p e0222653 (2019)
PLoS ONE
PLoS ONE
GPR40/FFAR1 is a Gq protein-coupled receptor expressed in pancreatic β cells and enteroendocrine cells, and mediates insulin and incretin secretion to regulate feeding behavior. Several GPR40 full agonists have been reported to reduce food intake in
Autor:
Hitomi Ogino, Tsuyoshi Maekawa, Masanori Watanabe, Mitsugi Ookawara, Koji Takeuchi, Yusuke Moritoh, Hirohisa Miyashita, Hikaru Ueno, Akihiro Kobayashi, Shin-ichi Abe, Nobuhiro Nishigaki, Tomoki Yoshihara, Yukio Yamada, Yoshiyuki Tsujihata, Ryo Ito, Yasufumi Miyamoto
Publikováno v:
The Journal of pharmacology and experimental therapeutics. 370(2)
The GPR40/FFA1 receptor is a G-protein-coupled receptor expressed in the pancreatic islets and enteroendocrine cells. Here, we report the pharmacological profiles of (3S)-3-cyclopropyl-3-{2-[(1-{2-[(2,2-dimethylpropyl)(6-methylpyridin-2-yl)carbamoyl]
Publikováno v:
Journal of Pharmacology and Experimental Therapeutics. 357:217-227
Sulfonylureas (SUs) are widely used insulin secretagogues, but they have adverse effects including hypoglycemia and secondary failure. Fasiglifam/TAK-875, a selective GPR40 agonist, enhances glucose-stimulated insulin secretion and improves hyperglyc
Publikováno v:
British Journal of Pharmacology. 170:568-580
Background and Purpose TAK-875, a selective GPCR40/free fatty acid receptor 1 agonist, improves glycaemic control by increasing glucose-dependent insulin secretion. Metformin is a first-line drug for treatment of type 2 diabetes that improves periphe
Autor:
Shuji Kitamura, Nobuyuki Negoro, Nobuhiro Suzuki, Tsuneo Yasuma, Yu Momose, Masami Suzuki, Naoyuki Kanzaki, Satoshi Mikami, Takashi Santou, Ryo Ito, Shinobu Sasaki, Takeshi Miyazaki, Junichi Miyazaki, Yoshiyuki Tsujihata, Toshimasa Tanaka, Miyuki Funami
Publikováno v:
Journal of Medicinal Chemistry. 55:3756-3776
As part of a program to identify potent GPR40 agonists with drug-like properties suitable for clinical development, the incorporation of polar substituents was explored with the intention of decreasing the lipophilicity of our recently disclosed phen
Autor:
Satoshi Mikami, Masami Suzuki, Yoshiyuki Tsujihata, Shinobu Sasaki, Takashi Santou, Masahiro Ito, Tomoyuki Odani, Toshimasa Tanaka, Nobuhiro Suzuki, Koji Takeuchi, Tsuneo Yasuma, Miyuki Funami, Shinichiro Matsunaga, Yu Momose, Junichi Miyazaki, Ryo Ito, Akifumi Kogame, Nobuyuki Negoro, Ayako Harada, Naoyuki Kanzaki
Publikováno v:
ACS Medicinal Chemistry Letters. 1:290-294
GPR40, one of the G protein-coupled receptors predominantly expressed in pancreatic β-cells, mediates enhancement of glucose-stimulated insulin secretion by free fatty acids. A potent and selective GPR40 agonist is theorized to be a safe and effecti
Autor:
Susumu Suzuki, Shigeo Kure, Hiroyuki Kagechika, Dai Suzuki, Akiko Saito-Hakoda, Sadayoshi Ito, William E. Rainey, Ikuma Fujiwara, Rehana Parvin, Atsushi Yokoyama, Akira Sugawara, Kyoko Shimizu, Hiroki Shimada, Erika Noro, Ryo Ito
Publikováno v:
PLoS ONE, Vol 12, Iss 8, p e0181055 (2017)
PLoS ONE
PLoS ONE
The effects of retinoids on adrenal aldosterone synthase gene (CYP11B2) expression and aldosterone secretion are still unknown. We therefore examined the effects of nuclear retinoid X receptor (RXR) pan-agonist PA024 on CYP11B2 expression, aldosteron
Autor:
Kazumasa Miyawaki, Kae Matsuda-Nagasumi, Koji Takeuchi, Yugo Habata, Hidetoshi Komatsu, Chiori Yabuki, Risa Maeda, Naoya Kikuchi, Kensuke Sakuma, Yoshiyuki Tsujihata, Masaaki Mori, Ryo Ito
Publikováno v:
PLoS ONE, Vol 8, Iss 10, p e76280 (2013)
PLoS ONE
PLoS ONE
Selective free fatty acid receptor 1 (FFAR1)/GPR40 agonist fasiglifam (TAK-875), an antidiabetic drug under phase 3 development, potentiates insulin secretion in a glucose-dependent manner by activating FFAR1 expressed in pancreatic β cells. Althoug